Literature DB >> 28581475

The choice of in-hospital or home administration for plerixafor injection to poor mobilizers has no adverse consequence on subsequent hematopoietic stem cell harvest.

C Chabannon1, F Bijou2, J-M Grouin3, P Drillat4, N Milpied5, M Mohty6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28581475     DOI： 10.1038/bmt.2017.103

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  8 in total

1.  A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.

Authors:  François Lefrère; Laeticia Mauge; Delphine Réa; Jean-Antoine Ribeil; Liliane Dal Cortivo; Anne C Brignier; Charbel Aoun; Jérôme Larghéro; Marina Cavazzana-Calvo; Jean-Michel Micléa
Journal:  Transfusion       Date:  2012-06-21       Impact factor: 3.157

Review 2.  The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation.

Authors:  M Mohty; R F Duarte; S Croockewit; K Hübel; G Kvalheim; N Russell
Journal:  Leukemia       Date:  2011-01       Impact factor: 11.528

3.  A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the "on-demand" scheme of administration at French autologous hematopoietic stem cell transplant programs.

Authors:  Christian Chabannon; Fontanet Bijou; Jean-Michel Miclea; Noel Milpied; Jean-Marie Grouin; Mohamad Mohty
Journal:  Transfusion       Date:  2015-05-13       Impact factor: 3.157

4.  The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone.

Authors:  Neal Flomenberg; Steven M Devine; John F Dipersio; Jane L Liesveld; John M McCarty; Scott D Rowley; David H Vesole; Karin Badel; Gary Calandra
Journal:  Blood       Date:  2005-05-12       Impact factor: 22.113

5.  Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist.

Authors:  W Conrad Liles; Elin Rodger; Hal E Broxmeyer; Christine Dehner; Karin Badel; Gary Calandra; Jeff Christensen; Brent Wood; Thomas H Price; David C Dale
Journal:  Transfusion       Date:  2005-03       Impact factor: 3.157

6.  Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.

Authors:  W Conrad Liles; Hal E Broxmeyer; Elin Rodger; Brent Wood; Kai Hübel; Scott Cooper; Giao Hangoc; Gary J Bridger; Geoffrey W Henson; Gary Calandra; David C Dale
Journal:  Blood       Date:  2003-07-10       Impact factor: 22.113

7.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Authors:  John F DiPersio; Edward A Stadtmauer; Auayporn Nademanee; Ivana N M Micallef; Patrick J Stiff; Jonathan L Kaufman; Richard T Maziarz; Chitra Hosing; Stefan Früehauf; Mitchell Horwitz; Dennis Cooper; Gary Bridger; Gary Calandra
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

8.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.